Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMND NASDAQ:EVFM NASDAQ:GLTO NASDAQ:INDP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMNDClearmind Medicine$0.99-3.2%$0.96$0.80▼$2.18$4.21M0.96316,884 shs26,698 shsEVFMEvofem Biosciences$0.01+4.3%$0.01$0.01▼$0.02$1.14M-0.99404,756 shs30,147 shsGLTOGalecto$3.38+3.7%$3.43$2.01▼$15.13$4.48M1.3534,487 shs10,032 shsINDPIndaptus Therapeutics$7.17+6.4%$10.11$6.65▼$58.24$4.10M1.149,002 shs20,320 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMNDClearmind Medicine0.00%+1.74%+0.71%+2.12%-23.49%EVFMEvofem Biosciences0.00%+5.49%+4.35%+12.94%-3.03%GLTOGalecto0.00%+4.81%-3.01%+23.36%-71.83%INDPIndaptus Therapeutics0.00%-1.78%-41.38%-36.08%-84.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMNDClearmind Medicine0.4314 of 5 stars0.02.00.00.02.61.70.0EVFMEvofem Biosciences0.6813 of 5 stars0.03.00.04.80.60.00.0GLTOGalecto2.8971 of 5 stars3.53.00.00.01.91.71.3INDPIndaptus Therapeutics2.9134 of 5 stars3.55.00.00.00.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMNDClearmind Medicine 0.00N/AN/AN/AEVFMEvofem Biosciences 0.00N/AN/AN/AGLTOGalecto 3.00Buy$10.00195.86% UpsideINDPIndaptus Therapeutics 3.00Buy$238.003,219.39% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/AEVFMEvofem Biosciences$11.39M0.10N/AN/A($2.64) per share0.00GLTOGalectoN/AN/AN/AN/A$7.26 per shareN/AINDPIndaptus TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMNDClearmind Medicine-$5.26M-$1.10N/A∞N/AN/A-164.79%-71.12%9/15/2025 (Estimated)EVFMEvofem Biosciences$52.98M-$0.05N/A∞N/A-46.42%-91.97%-61.93%N/AGLTOGalecto-$21.44M-$13.13N/AN/AN/AN/A-115.70%-95.42%8/11/2025 (Estimated)INDPIndaptus Therapeutics-$15.02M-$41.74N/AN/AN/AN/A-333.02%-216.36%8/11/2025 (Estimated)Latest EVFM, GLTO, INDP, and CMND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025N/AINDPIndaptus Therapeutics-$0.36N/AN/AN/AN/AN/A8/5/2025Q2 2025GLTOGalectoN/A-$2.60N/A-$2.60N/AN/A6/12/2025Q2 2025CMNDClearmind MedicineN/A-$0.16N/A-$0.16N/AN/A5/14/2025Q1 2025INDPIndaptus Therapeutics-$11.48-$8.96+$2.52-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMNDClearmind MedicineN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AGLTOGalectoN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMNDClearmind MedicineN/A1.741.74EVFMEvofem BiosciencesN/A0.110.09GLTOGalectoN/A4.969.62INDPIndaptus TherapeuticsN/A1.901.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMNDClearmind Medicine96.05%EVFMEvofem Biosciences0.22%GLTOGalecto14.20%INDPIndaptus Therapeutics7.06%Insider OwnershipCompanyInsider OwnershipCMNDClearmind MedicineN/AEVFMEvofem Biosciences0.21%GLTOGalecto10.80%INDPIndaptus Therapeutics20.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableEVFMEvofem Biosciences120118.66 million113.12 millionNot OptionableGLTOGalecto401.32 million1.18 millionOptionableINDPIndaptus Therapeutics6570,000454,000Not OptionableEVFM, GLTO, INDP, and CMND HeadlinesRecent News About These CompaniesIndaptus Therapeutics (INDP) to Release Earnings on Monday4 hours ago | americanbankingnews.comIndaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and WarrantsJuly 1, 2025 | globenewswire.comIndaptus Therapeutics Announces Reverse Stock Split - FinanzNachrichten.deJune 26, 2025 | finanznachrichten.deIndaptus Therapeutics, Inc. Announces One-for-Twenty-Eight Reverse Stock Split to Enhance Nasdaq Compliance and Attract InvestorsJune 26, 2025 | nasdaq.comIndaptus Therapeutics Announces Reverse Stock SplitJune 25, 2025 | globenewswire.comIndaptus Therapeutics, Inc. Secures $2.3 Million Through Convertible Promissory Notes and Warrants in Funding RoundJune 13, 2025 | quiverquant.comQIndaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and WarrantsJune 13, 2025 | globenewswire.comIndaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor TislelizumabJune 2, 2025 | globenewswire.comIndaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comIndaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development SummitMay 8, 2025 | globenewswire.comIndaptus Therapeutics, Inc. Common StockMarch 30, 2025 | fxempire.comFIndaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 SummitMarch 25, 2025 | globenewswire.comIndaptus Therapeutics reports new data on Phase 1 trial of Decoy20March 21, 2025 | markets.businessinsider.comIndaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20March 20, 2025 | globenewswire.comIndaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor TislelizumabMarch 18, 2025 | globenewswire.comIndaptus Therapeutics reports FY24 EPS ($1.61) vs ($1.83) last yearMarch 13, 2025 | markets.businessinsider.comIndaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate UpdateMarch 13, 2025 | globenewswire.comRegistration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025March 12, 2025 | globenewswire.comIndaptus Therapeutics expands patent portfolio in China, Japan, IsraelMarch 4, 2025 | markets.businessinsider.comIndaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer TreatmentsMarch 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVFM, GLTO, INDP, and CMND Company DescriptionsClearmind Medicine NASDAQ:CMND$0.99 -0.03 (-3.24%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.00 +0.01 (+0.91%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Evofem Biosciences NASDAQ:EVFM$0.0096 +0.00 (+4.35%) As of 08/8/2025 12:12 PM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Galecto NASDAQ:GLTO$3.38 +0.12 (+3.68%) Closing price 08/8/2025 02:48 PM EasternExtended Trading$3.40 +0.02 (+0.71%) As of 08/8/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Indaptus Therapeutics NASDAQ:INDP$7.17 +0.43 (+6.38%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$7.17 0.00 (0.00%) As of 08/8/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
